ARVN
BEARISH
$12.18
Live
Arvinas, Inc. · NASDAQ
Target $14.56
(+19.6%)
$5.9
52W Range
$14.51
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$782.25M
P/E
N/A
ROE
-16.2%
Profit margin
-30.8%
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ARVN's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score suggests no solvency validation. Despite a strong gross margin of 100.00%, the company reports a -30.77% profit margin, -754.74% operating margin, and an 84% YoY revenue decline, signaling fundamental business deterioration. Insider selling activity totaling $0.83M over six months, with multiple officer and CEO sales, reinforces bearish sentiment. While the stock has rebounded 42.5% over the past year, this is likely driven by speculative momentum rather than fundamentals, and the current price of $12.18 remains elevated relative to its deteriorating performance.
Key Strengths
Gross margin of 100.00% indicates potential product pricing power or low production costs
Extremely low debt/equity ratio of 0.02 suggests minimal financial leverage risk
High current and quick ratios (4.92 and 4.86) reflect strong short-term liquidity
Analyst consensus recommends 'buy' with a target price of $14.56, indicating some market optimism
Recent 6-month price surge of 57.4% suggests strong short-term momentum
Key Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
84% YoY revenue decline and negative operating margin (-754.74%) indicate business contraction and unsustainable operations
Insider selling of $0.83M in the last 6 months, including CEO and officer sales, signals loss of confidence
No positive profitability metrics: negative ROE (-16.23%), ROA (-7.94%), and negative forward P/E (-3.49)
No dividend, no free cash flow, and no intrinsic value or Graham Number available, indicating no defensive or value characteristics
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
8
Weak
10
15
10
5
0
AI Verdict
Weak
Key drivers: Piotroski F-Score of 0/9, Negative profitability and revenue contraction, Insider selling, No valuation anchors (Graham, Intrinsic), High price volatility and poor historical returns
Confidence
85%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 2.98 is below sector average of 164.64 (though meaningless due to sector-wide negative margins)
- Low debt/equity ratio suggests financial safety
Watchpoints
- No P/E, PEG, or Graham Number available
- Forward P/E of -3.49 indicates no earnings expectations
- Price/Book of 1.78 is not supported by profitability
- No intrinsic value model applicable due to negative earnings and growth
Future
15/100
Ref Growth rates
Positives
- Analyst target price of $14.56 suggests potential upside
- Recent 6-month price increase of 57.4% indicates momentum
Watchpoints
- 84% YoY revenue decline indicates severe business contraction
- No earnings growth data available, but forward P/E is negative
- No positive growth indicators in any metric
- Highly speculative future outlook with no earnings foundation
Past
10/100
Ref Historical trends
Positives
- 52-week high of $14.51 is above current price, suggesting recovery potential
- 1-year return of +42.5% shows recent outperformance
Watchpoints
- 5-year return of -84.3% reflects long-term underperformance
- 3-year return of -57.8% shows persistent decline
- Recent 1-month and 1-week declines of -7.0% and -10.4% indicate weakening momentum
- Historical price volatility and poor returns
Health
5/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity of 0.02 indicates minimal leverage risk
- Current and quick ratios of 4.92 and 4.86 suggest strong liquidity
Watchpoints
- Piotroski F-Score of 0/9 is the lowest possible, indicating complete operational failure
- No Altman Z-Score available, but the financial health indicators are severely deteriorated
- Negative ROE, ROA, and operating margin signal deep profitability issues
- No free cash flow or operating cash flow data available
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength score of 0/100
- No history or expectation of dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$12.18
Analyst Target
$14.56
Upside/Downside
+19.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ARVN and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ARVN
Arvinas, Inc.
Primary
|
-84.3% | -57.8% | +42.5% | +57.4% | -7.0% | -10.4% |
|
MGTX
MeiraGTx Holdings plc
Peer
|
-29.7% | +81.4% | +75.7% | +23.0% | +30.3% | +1.2% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
|
OMDA
Omada Health, Inc.
Peer
|
-43.0% | -43.0% | -43.0% | -48.4% | -11.3% | +4.7% |
|
IART
Integra LifeSciences Holdings Corporation
Peer
|
-85.7% | -83.0% | -43.2% | -25.8% | +3.0% | +3.9% |
ARV
Arvinas, Inc.
Primary
5Y
-84.3%
3Y
-57.8%
1Y
+42.5%
6M
+57.4%
1M
-7.0%
1W
-10.4%
MGT
MeiraGTx Holdings plc
Peer
5Y
-29.7%
3Y
+81.4%
1Y
+75.7%
6M
+23.0%
1M
+30.3%
1W
+1.2%
AMN
AMN Healthcare Services, Inc.
Peer
5Y
-72.8%
3Y
-78.8%
1Y
-26.3%
6M
+3.5%
1M
+28.0%
1W
+7.7%
OMD
Omada Health, Inc.
Peer
5Y
-43.0%
3Y
-43.0%
1Y
-43.0%
6M
-48.4%
1M
-11.3%
1W
+4.7%
IAR
Integra LifeSciences Holdings Corporation
Peer
5Y
-85.7%
3Y
-83.0%
1Y
-43.2%
6M
-25.8%
1M
+3.0%
1W
+3.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-3.49
PEG Ratio
N/A
P/B Ratio
1.78
P/S Ratio
2.98
EV/Revenue
0.39
EV/EBITDA
-0.92
Market Cap
$782.25M
Profitability
Profit margins and return metrics
Profit Margin
-30.77%
Operating Margin
-754.74%
Gross Margin
100.0%
ROE
-16.23%
ROA
-7.94%
Growth
Revenue and earnings growth rates
Revenue Growth
-84.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
4.92
Strong
Quick Ratio
4.86
Excellent
Cash/Share
$10.72
Healthcare Sector Comparison
Comparing ARVN against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-16.23%
This Stock
vs
-88.14%
Sector Avg
-81.6%
(Below Avg)
Profit Margin
-30.77%
This Stock
vs
-16.28%
Sector Avg
+89.0%
(Superior)
Debt to Equity
0.02
This Stock
vs
2.66
Sector Avg
-99.2%
(Less Debt)
Revenue Growth
-84.0%
This Stock
vs
124.04%
Sector Avg
-167.7%
(Slower)
Current Ratio
4.92
This Stock
vs
4.47
Sector Avg
+9.9%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ARVN
Arvinas, Inc.
|
BEARISH | $782.25M | - | -16.2% | -30.8% | $12.18 | |
|
MGTX
MeiraGTx Holdings plc
|
NEUTRAL | $784.33M | - | -368.2% | -140.3% | $9.63 | Compare |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | Compare |
|
OMDA
Omada Health, Inc.
|
BEARISH | $773.1M | - | -8.7% | -4.9% | $13.12 | Compare |
|
IART
Integra LifeSciences...
|
NEUTRAL | $771.58M | - | -39.9% | -31.6% | $9.9 | Compare |
ARVN
Arvinas, Inc.
BEARISH
Mkt Cap
$782M
P/E
-
ROE
-16.2%
Price
$12.18
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | MORRISON BRIGGS W. M.D. | Director | Purchase | 20,000 | $268,070 |
| 2026-02-27 | HOUSTON JOHN G | Director | Sale | 35,297 | $466,154 |
| 2026-02-26 | LOOMIS DAVID K | Officer | Stock Award | 12,420 | - |
| 2026-02-26 | TEEL RANDY PH.D. | Chief Executive Officer | Stock Award | 147,791 | - |
| 2026-02-26 | CACACE ANGELA M | Officer | Stock Award | 45,000 | - |
| 2026-02-26 | BERKOWITZ NOAH | Officer | Stock Award | 45,000 | - |
| 2026-02-26 | SAIK ANDREW | Chief Financial Officer | Stock Award | 45,000 | - |
| 2026-02-23 | LOOMIS DAVID K | Officer | Sale | 1,108 | $13,473 |
| 2026-02-23 | TEEL RANDY PH.D. | Chief Executive Officer | Sale | 4,786 | $58,198 |
| 2026-02-23 | CACACE ANGELA M | Officer | Sale | 3,609 | $43,885 |
| 2026-02-13 | LOOMIS DAVID K | Officer | Sale | 1,016 | $12,080 |
| 2026-02-13 | TEEL RANDY PH.D. | Chief Executive Officer | Sale | 4,403 | $52,352 |
| 2026-02-13 | CACACE ANGELA M | Officer | Sale | 4,592 | $54,599 |
| 2026-02-13 | BERKOWITZ NOAH | Officer | Sale | 5,685 | $67,595 |
| 2026-02-13 | SAIK ANDREW | Chief Financial Officer | Sale | 5,134 | $61,043 |
MORRISON BRIGGS W. M.D.
Director
2026-03-06
20,000 shares
·
$268,070
HOUSTON JOHN G
Director
2026-02-27
35,297 shares
·
$466,154
LOOMIS DAVID K
Officer
2026-02-26
12,420 shares
TEEL RANDY PH.D.
Chief Executive Officer
2026-02-26
147,791 shares
CACACE ANGELA M
Officer
2026-02-26
45,000 shares
BERKOWITZ NOAH
Officer
2026-02-26
45,000 shares
SAIK ANDREW
Chief Financial Officer
2026-02-26
45,000 shares
LOOMIS DAVID K
Officer
2026-02-23
1,108 shares
·
$13,473
TEEL RANDY PH.D.
Chief Executive Officer
2026-02-23
4,786 shares
·
$58,198
CACACE ANGELA M
Officer
2026-02-23
3,609 shares
·
$43,885
LOOMIS DAVID K
Officer
2026-02-13
1,016 shares
·
$12,080
TEEL RANDY PH.D.
Chief Executive Officer
2026-02-13
4,403 shares
·
$52,352
CACACE ANGELA M
Officer
2026-02-13
4,592 shares
·
$54,599
BERKOWITZ NOAH
Officer
2026-02-13
5,685 shares
·
$67,595
SAIK ANDREW
Chief Financial Officer
2026-02-13
5,134 shares
·
$61,043
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
16 analysts
Citigroup
2026-03-05
Buy
Buy
Piper Sandler
2026-02-25
Overweight
Overweight
Evercore ISI Group
2026-02-25
Outperform
Outperform
Wedbush
2026-02-25
Neutral
Neutral
Citigroup
2026-01-06
Neutral
Buy
Barclays
2025-12-17
Overweight
Overweight
Stephens & Co.
2025-11-10
Overweight
Overweight
Wells Fargo
2025-11-06
Overweight
Overweight
Barclays
2025-11-06
Overweight
Overweight
BTIG
2025-10-30
Buy
Buy
Past News Coverage
Recent headlines mentioning ARVN from our newsroom.
Newest → oldest
No matching news yet.